Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
Exclusive agreement for rabies monoclonal antibodies to fight fatal disease
04-Jan-2008 -
Crucell N.V. announced that it has signed an exclusive collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine ...
clinical trials
Crucell
food
+8